Fosun Pharma subsidiary inks GLP-1R agonist deal with Pfizer

Chongqing Yaoyou Pharmaceutical, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has signed a licensing agreement with Pfizer Inc. for its oral small molecule GLP-1R agonist, YP05002. This agreement grants Pfizer exclusive global rights for development, use, manufacturing, and commercialization across all human and animal indications. Under the deal, Yaoyou will receive an upfront payment of $15,000m and up to $35,000m in development milestone payments, with potential sales milestone payments of up to $158,500m, and royalties based on net annual sales.

YP05002, currently in Phase I clinical trials in Australia, is an independently developed drug targeting type 2 diabetes, obesity, and related metabolic diseases. In a separate development, Fosun Pharma also announced that its subsidiary Shanghai Henlius Biotech, Inc. received approval from China's NMPA for clinical trials of HLX22 (recombinant humanized anti-HER2 monoclonal antibody) in combination with HLX87 (HER2 antibody-drug conjugate) for HER2-positive breast cancer.

These approvals represent significant steps for Fosun Pharma's innovative drug pipeline, aiming to accelerate clinical development and commercialization. Both drug development processes involve inherent risks and uncertainties, including clinical trial outcomes and market dynamics.